Bettina Schunack

Learn More
Canine vector-borne diseases (CVBDs) have increasingly become a focus of attention in the past few years. Nevertheless, in many parts of Europe information on their occurrence is still scarce. In a large study in Poland 3,094 serum samples taken from dogs throughout all 16 Polish provinces were tested using a commercial kit for the detection of circulating(More)
The ability of the topical spot-on Advantix® (50 % permethrin/10 % imidacloprid) to prevent transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs has previously been reported. The recent market introduction of chewable tablets containing the novel compounds, afoxolaner (NexGard™) and fluralaner (Bravecto™) enabled us to conduct(More)
Speed of kill, repellent (anti-feeding) and acaricidal efficacy of an imidacloprid 10 % (w/w) /flumethrin 4.5 % (w/w) collar (Seresto®, Bayer) and a spot-on formulation of fipronil 8.3 % (w/v) /(S)-methoprene 10 % (w/v) /eprinomectin 0.4 % (w/v) /praziquantel 8.3 % (w/v) (Broadline®, Merial) against artificiallyinduced infestations with Ixodes ricinus on(More)
Safety of concomitant use of veterinary products is of clinical interest. A series of studies was performed to evaluate the chemical compatibility and short term dermal and systemic safety of an imidacloprid/flumethrin collar (Seresto®/ Foresto®, Bayer) used concomitantly with spot-on or tablet formulations. Chemical compatibility was evaluated in-vitro(More)
  • 1